Teligent Inc (TLGT) reported quarterly earnings results on Thursday, Apr-28-2016. The company said it had a profit of $0.02 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.06. Analysts had a consensus of $-0.04. The company posted revenue of $15.70 million in the period, compared to analysts expectations of $14.33 million. The company’s revenue was up 46.7% compared to the same quarter last year.
Many Wall Street Analysts have commented on Teligent Inc. Shares were Reiterated by Deutsche Bank on Mar 10, 2016 to “Hold” and Lowered the Price Target to $ 8 from a previous price target of $9 .
In a different news, on Mar 14, 2016, Jason Grenfell-gardner (CEO) purchased 10,500 shares at $4.82 per share price.
Teligent Inc. formerly IGI Laboratories Inc. is a specialty generic pharmaceutical company. The Company is engaged in the manufacture and development of topical pharmaceutical over-the-counter (OTC) and cosmetic products. The Company under its label sells generic topical pharmaceutical products that are bioequivalent to their brand name counterparts. The Company has two platforms for growth: developing manufacturing and marketing a range of generic pharmaceutical products under its label in topical injectable complex and ophthalmic dosage forms and managing its contract manufacturing and formulation services business. The Company’s contract manufacturing and development business includes two services: contract formulation and contract manufacturing. The Company’s products are used in a range of applications such as cosmetics and prescription treatment of conditions such as dermatitis psoriasis and eczema.